Pharmaceutical Non-Active Ingredients TRIZ Cases

Segmenting saponin and effector conjugates overcomes off-target toxicity while enhancing targeted cancer cell uptake.

Spacer molecules separate fluorescent labels from antibodies, reducing quenching and boosting emission intensity by up to 500%.

A renal excretion-type fluorescence contrast agent emits near infrared light for high-resolution tumor visualization.

Lipid binding protein complexes protect cyclic dinucleotides from phosphodiesterase degradation while preserving STING pathway activation potency.

Gelatin film with surfactant achieves pH-dependent dissolution, eliminating coating complexity and defects.

DNA templates guide reactive oligonucleotides to metal binding sites, enabling site-selective conjugation without genetic engineering.

A kneader reactor with orbitally revolving stirring blades applies shear force during esterification to produce hydroxypropyl methyl cellulose phthalate.

Chemical coupling linker achieves site-specific antibody conjugation, resolving plasma instability and non-specific binding to maintain drug efficacy.

Self-stabilizing linkers prevent maleimide transfer to plasma thiols by catalyzing succinimide ring hydrolysis, ensuring stable drug payload retention.

A single-domain antibody conjugated to saponin transfers therapeutic cargo into target cells via specific binding and membrane interaction.

Twin-screw extrusion granulates binder and superdisintegrant together, preserving superdisintegrant stability while ensuring batch consistency.

A tumor-targeted retrovector delivers a cytocidal dominant-negative cyclin G1 construct to cancer cells.

Hyaluronic acid conjugates deliver antitumoral drugs locally, reducing systemic absorption and side-effects.

A fibre-free transdermal therapeutic system uses a skin-colored adhesive layer to create an inconspicuous patch.

Composite locust bean gum and acacia resolve structural integrity versus dissolution speed contradictions, achieving 15-minute disintegration.

Modified solvent processing preserves granule cohesion during functionalization, enabling dual-rate release in high-loading monolithic tablets.

A gastroretentive dosage form combines polyethylene oxide swelling agents with ethyl cellulose retardants to voluminously expand within the stomach.

Sortase-mediated conjugation creates stable anthracycline-drug conjugates with defined ratios, preventing non-specific toxin release in serum.

Covalent PBAE bonding on AAV capsids protects viral particles from neutralizing antibodies while maintaining stability during intravenous injection.

Multi-protease cleavable peptides segment functional domains to reduce off-target effects while maintaining normal tissue integrity.

Alternating hydrophilic-hydrophobic copolymers traverse lipid bilayers to transport active ingredients across cell membranes.

A hydrophilic polymer derivative uses a self-immolative acetal linker to release active drugs via pH-dependent cleavage.

Peptide-carrier conjugates deliver active agonists to target cells, reducing systemic side effects while treating Type 2 diabetes.

Ionic complexes between polycationic and polyanionic agents enhance transfection efficiency while preserving protein integrity.

Anti-HER2 immunoconjugates merge targeting antibodies with immune adjuvants to overcome limited accessibility of inaccessible tumors.

Boswellic acids suppress pro-inflammatory cytokines like IL-6 and TNF-alpha, resolving the trade-off between viral clearance and severe inflammation.

Adding free thiourea protects thiourea-linked conjugates from deterioration under thermal stress, ensuring immunoassay performance.

Microgravity manufacturing produces uniform nanoparticles with picometer dimensions using supercritical fluid encapsulation.

Cadexomer iodine forms a stable complex that extends contact duration, reducing keloid size by 25% to 75%.

Dual TLR7/8-TLR2 conjugates overcome poor tumor penetration by leveraging electrostatic interactions for enhanced nucleic acid delivery.

Chemical crosslinkers replace genetic engineering to produce homogeneous bispecific antibodies with controlled molecular formats.

Acyl borate reagents enable near-quantitative drug release via reversible amide linkages, overcoming slow kinetics and instability of thiol-maleimide chemistry.

Hydrophilic functionalized particles improve aqueous solubility and bioavailability of poorly soluble hydrophobic drugs.

An additive composition combining L-HPC, crospovidone, and microcrystalline cellulose resolves the trade-off between tablet hardness and disintegration time.

Combining high and low molecular weight hydroxypropyl cellulose resolves cracking issues while maintaining durability on moving skin.

Replacing gelatin with a pullulan composite of gellan and potassium chloride maintains mechanical strength for vegetarian applications.

Anti-BCMA antibody drug conjugates resolve the efficacy-toxicity trade-off by selectively delivering cytotoxic payloads to BCMA-expressing cancer cells.

Amphipathic polymer nanoparticles target activated macrophages in atherosclerotic plaques, resolving low selectivity and high systemic dosage requirements.

Intrinsic fluorophores merge with biodegradable blocks to enable real-time implant degradation monitoring without cytotoxicity.

Thiolated antioxidants suppress oxidative degradation in lipid formulations, resolving compatibility issues with conventional stabilizers.

LDL-like nanoparticles encapsulate poorly water-soluble drugs within a lipid core modified with PEG and targeting antibodies.

Heterobifunctional compounds recruit deubiquitinases to remove ubiquitin chains, preventing proteasomal degradation of mutant proteins.

Hydrolyzable Si-N linkages enable controlled therapeutic agent release from polymers in aqueous environments.

A polymerizable composition forms an elastic in situ seal that stabilizes wounds and stops bleeding.

Calcium-mediated anionic polyplexes protect nucleic acids from degradation while enabling efficient cellular uptake without cytotoxicity.

Porous electrospun nanofiber scaffolds sustain therapeutic release over weeks by balancing rapid burst kinetics with prolonged diffusion pathways.

Targeting CD206-expressing macrophages alters cyto-states to reduce severity of pulmonary disease and disseminated thrombosis.